Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: An observational, long-term registry study

International Journal of Clinical Practice

Volumn 68, Issue 3, 2014, Pages 314-329

  Traish, A M ^a   Haider, A ^b   Doros, G ^c   Saad, F ^d,e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Private Urology Practice   (Germany)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Bayer Healthcare   (Germany)

^e GULF MEDICAL UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; ANDROGEN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL OBESITY; ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CARDIOMETABOLIC RISK; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE SIZE; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANATOMY AND HISTOLOGY; BLOOD; BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFECTS; HYPOGONADISM; LIPID METABOLISM; LONG TERM CARE; METABOLISM; MIDDLE AGED; OBESITY; ORGAN SIZE; PATHOPHYSIOLOGY; PROSTATE; REGISTER; TREATMENT OUTCOME;

ADULT; AGED; ANDROGENS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGONADISM; LIPID METABOLISM; LONG-TERM CARE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ORGAN SIZE; PROSTATE; REGISTRIES; TESTOSTERONE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84896689377     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12319     Document Type: Article

References (126)

1. Aub JC,. The use of testosterone. N Engl J Med 1940; 222: 877-81.
2. Aub JC, Kety SS,. Recent advances in testosterone therapy. N Engl J Med 1943; 228: 338-43.
3. Traish AM, Kypreos KE,. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011; 214: 244-8.
4. Kelly DM, Jones TH,. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217: R47-71.
5. Kelly DM, Jones TH,. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013; 217: R25-45.
6. Rao PM, Kelly DM, Jones TH,. Testosterone and insulin resistance in the metabolic syndrome and type 2 diabetes. Nat Rev Endocrinol 2013; 9: 479-3.
7. Saad F, Aversa A, Isidori AM, Gooren LJ,. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012; 8: 131-43.
8. Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34: 1669-75.
9. Traish AM, Guay A, Feeley R, Saad F,. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22.
10. Traish AM, Saad F, Guay A,. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23-32.
11. Traish AM, Saad F, Feeley RJ, Guay A,. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-94.
12. Traish AM, Miner MM, Morgentaler A, Zitzmann M,. Testosterone deficiency. Am J Med 2011; 124: 578-87.
13. Traish AM, Abdou R, Kypreos KE,. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009; 51: 303-13.
14. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-92.
15. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P,. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462-8.
16. Ding EL, Song Y, Malik VS, Liu S,. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-99.
17. Corona G, Mannucci E, Petrone L, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006; 18: 190-7.
18. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165: 687-701.
19. Corona G, Rastrelli G, Monami M, et al. Body mass index regulates hypogonadism-associated cv risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 2011; 8: 2098-105.
20. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-83.
21. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M,. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011; 34: 557-67.
22. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013; 168: 829-43.
23. Kapoor D, Goodwin E, Channer KS, Jones TH,. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
24. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH,. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595-602.
25. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT,. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40: 189-207.
26. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L,. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889-97.
27. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB,. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490-4.
28. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL,; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
29. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.
30. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB,. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-50.
31. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92: 3568-72.
32. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-8.
33. Haring R, Völzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009; 58: 2027-31.
34. Saad F,. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev 2012; 28 (Suppl. 2): 52-9.
35. Li C, Ford ES, Li B, Giles WH, Liu S,. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010; 33: 1618-24.
36. Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32: 720-8.
37. Camacho EM, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-55.
38. Muraleedharan V, Jones TH,. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab 2010; 1: 207-23.
39. Mårin P,. Testosterone and regional fat distribution. Obes Res 1995; 3 (Suppl. 4): 609S-12S.
40. Mårin P, Odén B, Björntorp P,. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80: 239-43.
41. Simon D, Charles M-A, Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001; 24: 2149-51.
42. Naharci MI, Pinar M, Bolu E, Olgun A,. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocrine Pract 2007; 13: 629-35.
43. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37.
44. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ,. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254-9.
45. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A,. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010; 33: 776-83.
46. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495-503.
47. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50.
48. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI,. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab 2008; 93: 139-46.
49. Saad F, Haider A, Doros G, Traish A,. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013. Advance online publication 22 Apr 2013, doi: 10.1002/oby.20407.
50. Nieschlag E, Behre HM, eds. Andrology. 1st edn. Berlin, Heidelberg, New York: Springer, 1997.
51. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011; 96: 2430-9.
52. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
53. Andriole GL, Crawford ED, Grubb RL 3rd, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
54. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90.
55. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ,. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 2012; 62: 757-64.
56. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20.
57. Morgentaler A,. Goodbye androgen hypothesis, hello saturation model. Eur Urol 2012; 62: 765-7.
58. Zitzmann M, Nieschlag E,. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844-53.
59. Page ST, Herbst KL, Amory JK, et al. Testosterone administration suppresses adiponectin levels in men. J Androl 2005; 26: 85-92.
60. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH,. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313-8.
61. Monroe AK, Dobs AS,. The effect of androgens on lipids. Curr Opin Endocrinol Diabetes Obes 2013; 20: 132-9.
62. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011; 58: 1674-81.
63. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
64. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63: 280-93.
65. Kypreos K,. HDL quality in atherosclerosis: can ratios between apolipoproteins of HDL be used effectively to indicate risk of premature myocardial infarction? Clin Lipidol 2012; 7: 127-9.
66. Tan KC, Shiu SW, Pang RW, Kung AW,. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf) 1998; 48: 187-94.
67. Rubinow KB, Tang C, Hoofnagle AN, et al. Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids 2012; 77: 454-60.
68. Rubinow KB, Vaisar T, Tang C, Matsumoto AM, Heinecke JW, Page ST,. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res 2012; 53: 1376-83.
69. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685-92.
70. Gimeno-Orna JA, Faure-Nogueras E, Sancho-Serrano MA,. [D] Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidaemia. Diabet Med 2005; 22: 26-31.
71. Kim SW, Jee JH, Kim HJ, et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol 2013 (in press). Advance online publication March 29 2013, doi: 10.1016/j.ijcard.2013.03.027
72. Bleda S, de Haro J, Varela C, Esparza L, Rodriguez J, Acin F,. Improving total-cholesterol/HDL-cholesterol ratio results in an endothelial dysfunction recovery in peripheral artery disease patients. Cholesterol 2012; 2012: 895326.
73. Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J,. Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromsø study. Nutr Metab Cardiovasc Dis 2008; 18: 256-62.
74. Maneschi E, Morelli A, Filippi S, et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 2012; 215: 347-62.
75. Jiann BP, Hsieh JT, Liu SP, Hsu SH, Wu HC,. Associations of endogenous testosterone and lipid profiles in middle-aged to older Taiwanese men. Int J Impot Res 2011; 23: 62-9.
76. Robinson JG, Wang S, Jacobson TA,. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012; 110: 1468-76.
77. Adams SP, Tsang M, Wright JM,. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2012; 12: CD008226.
78. Permpongkosol S, Tantirangsee N, Ratana-olarn K,. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010; 7: 3765-3674.
79. Jones TH,. Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes 2010; 2: 146-56.
80. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJG, Giltay EJ, Saad F,. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol 2010; 73: 602-12.
81. Barud W, Palusiński R, Bełtowski J, Wõjcicka G,. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 2002; 164: 283-8.
82. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-5.
83. Mäkinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 2008; 197: 688-93.
84. Barrett-Connor E, Khaw KT,. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539-45.
85. Barrett-Connor E,. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807-11.
86. Haffner SM, Valdez RA, Stern MP, Katz MS,. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993; 17: 643-9.
87. Haffner SM, Mykkänen L, Valdez RA, Katz MS,. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610-5.
88. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM,. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166: 95-102.
89. Stanworth RD, Kapoor D, Channer KS, Jones TH,. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clin Endocrinol 2011; 74: 624-30.
90. Agledahl I, Hansen JB, Svartberg J,. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest 2008; 68: 641-8.
91. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M,. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013; 10: 579-88.
92. Boyanov MA, Boneva Z, Christov VG,. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.
93. Heufelder AE, Saad F, Bunck MC, Gooren L,. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-33.
94. Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM,. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Registry Testim in the US (TRiUS). BMC Endocr Disord 2011; 11: 18-29.
95. Reckelhoff JF,. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199-208.
96. Dubey RK, Oparil S, Imthum B, Jackson EK,. Sex hormones and hypertension. Cardiovasc Res 2002; 53: 688-708.
97. Fogari R, Preti P, Zoppi A, et al. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res 2005; 28: 625-30.
98. Svartberg J, von Mühlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R,. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004; 150: 65-71.
99. Li JY, Zhu JC, Dou JT, et al. Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male 2002; 5 (1): 47-51.
100. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261.
101. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C,. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003; 104: 195.
102. Brand JS, Wareham NJ, Dowsett M, et al. Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clin Endocrinol (Oxf) 2011; 74: 572-8.
103. Sasaki J, Otonari T, Uchida Y, Ikeda Y, Biro S, Kono S,. Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT Study. J Atheroscler Thromb 2013; 20: 368-79.
104. Richard C, Couture P, Desroches S, Lamarche B,. Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. Obesity (Silver Spring) 2013; 21: 51-7.
105. Musani SK, Vasan RS, Bidulescu A, et al. Aldosterone, C-reactive protein, and plasma b-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care 2013; 36: 3084-92.
106. Jung CH, Lee WY, Kim SY, et al. The risk of metabolic syndrome according to the high-sensitivity C-reactive protein in apparently healthy Koreans. Int J Cardiol 2008; 129: 266-71.
107. Ridker PM, Wilson PWF, Grandy SM,. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-25.
108. Siest G, Schiele F, Galteau MM, et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975; 21: 1077-87.
109. Pratt DS, Kaplan MM,. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 27: 1266-71.
110. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
111. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
112. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS,. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-44.
113. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J,. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 2009; 104: 1715-22.
114. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY,. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012; 167: 531-41.
115. Gates MA, Mekary RA, Chiu GR, Ding EL, Wittert GA, Araujo AB,. Sex steroid hormone levels and body composition in men. J Clin Endocrinol Metab 2013; 98 (6): 2442-50.
116. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA,. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.
117. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM,. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97: 2050-8.
118. De Maddalena C, Vodo S, Petroni A, Aloisi AM,. Impact of testosterone on body fat composition. J Cell Physiol 2012; 227: 3744-8.
119. Traish AM, Toselli P, Jeong SJ, Kim NN,. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242-8.
120. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147 (1): 141-54.
121. Blouin K, Nadeau M, Perreault M, et al. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf) 2010; 72: 176-88.
122. Blouin K, Veilleux A, Luu-The V, Tchernof A,. Androgen metabolism in adipose tissue: recent advances. Mol Cell Endocrinol 2009; 301: 97-103.
123. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-83.
124. Firtser S, Juonala M, Magnussen CG, et al. Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012; 222: 257-62.
125. Niswender K,. Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obes Metab 2010; 12: 267-87.
126. Hildreth KL, Barry DW, Moreau KL, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98: 1891-900.